Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $41.00 at The Goldman Sachs Group

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price upped by The Goldman Sachs Group from $36.00 to $41.00 in a research report report published on Friday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms also recently weighed in on TARS. Oppenheimer increased their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $44.83 on Friday. Tarsus Pharmaceuticals has a 12 month low of $15.60 and a 12 month high of $52.99. The company has a current ratio of 5.42, a quick ratio of 6.99 and a debt-to-equity ratio of 0.30. The business’s 50 day simple moving average is $37.84 and its 200 day simple moving average is $32.53. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently bought and sold shares of TARS. Swiss National Bank boosted its holdings in Tarsus Pharmaceuticals by 1.4% in the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after purchasing an additional 600 shares during the period. Alpha DNA Investment Management LLC grew its position in Tarsus Pharmaceuticals by 9.1% during the second quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock worth $412,000 after buying an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after acquiring an additional 1,530 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 26.8% in the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock valued at $248,000 after acquiring an additional 1,929 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $61,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.